Ajanta Pharma hits new high on USFDA approval; shares up 3%

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol BureauShare price of Ajanta Pharma touched 52-week high, rises 3 percent intraday Friday on the back of US Food and Drug Administration (USFDA) approval for oral suspension drug.The company has received a final approval from USFDA for Omeprazole and Sodium Bicarbonate Powder for oral suspension, which is bioequivalent generic version of Zegerid 1 powder for oral suspension.The company will be launching this product soon in 2 strengths 20 mg / 1680 mg and 40 mg / 1680 mg powder sachets.The company has total 26 abbreviated new drug application (ANDA) of which it has final approvals for 12 ANDAs, 1 tentative approval and 13 ANDAs are under review with USFDA. At 10:47 hrs Ajanta Pharma was quoting at Rs 1,747.65, up Rs 22.05, or 1.28 percent on the BSE.Posted by Rakesh Patil